NCT04983888 is a Phase 2 clinical trial of Obinutuzumab in Primary Focal Segmental Glomerulosclerosis, sponsored by Mayo Clinic.

Who is sponsoring NCT04983888?

NCT04983888 is sponsored by Mayo Clinic.

What drugs are being tested in NCT04983888?

Interventions in NCT04983888: Obinutuzumab.

What condition does NCT04983888 study?

NCT04983888 studies Primary Focal Segmental Glomerulosclerosis.

Is NCT04983888 still recruiting?

NCT04983888 is currently completed. Last updated 11 September 2025.

Last reviewed 2025-09-11 · How we verify

NCT04983888

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Obinutuzumab in Primary FSGS

Completed Phase 2 Last updated 11 September 2025

What this trial tests

Phase 2 trial testing Obinutuzumab in Primary Focal Segmental Glomerulosclerosis in 20 participants. Completed in 16 June 2025.

Timeline

17 November 2021

Primary endpoint
16 June 2025

16 June 2025

Quick facts

Lead sponsor	Mayo Clinic
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	17 November 2021
Primary completion	16 June 2025
Estimated completion	16 June 2025
Sites	1 location across United States

Drugs / interventions tested

Obinutuzumab — full drug profile →

Conditions studied

Primary Focal Segmental Glomerulosclerosis — all drugs for Primary Focal Segmental Glomerulosclerosis →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Primary Focal Segmental Glomerulosclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Obinutuzumab in Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome in Children.
Dossier C, Bonneric S, Baudouin V, Kwon T, et al · · 2023 · cited 42× · PMID 37678236 · DOI 10.2215/cjn.0000000000000288
Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives.
Hartinger JM, Kratky V, Hruskova Z, Slanar O, et al · · 2022 · cited 30× · PMID 36420256 · DOI 10.3389/fimmu.2022.1024068
Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.
Mirioglu S, Daniel-Fischer L, Berke I, Ahmad SH, et al · · 2024 · cited 23× · PMID 38341276 · DOI 10.1093/ndt/gfae025
Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis.
de Cos M, Meliambro K, Campbell KN. · · 2023 · cited 22× · PMID 36644367 · DOI 10.1016/j.ekir.2022.10.004
Advances in Focal Segmental Glomerulosclerosis Treatment From the Perspective of the Newest Mechanisms of Podocyte Injury.
Zhu Y, Xu G. · · 2025 · cited 2× · PMID 39935575 · DOI 10.2147/dddt.s498457
Obinutuzumab in kidney transplantation: Past, present, and future.
Favi E, Morabito M. · · 2025 · PMID 41357414 · DOI 10.5500/wjt.v15.i4.108982
Obinutuzumab, an Anti-CD20, in Refractory Adult Autoimmune Podocytopathies: Report of 2 Cases.
Loeffler T, Flahault A, Alla A, Frimat L, et al · · 2025 · PMID 40837251 · DOI 10.1016/j.xkme.2025.101057

Verify or expand the search:

Other trials of Obinutuzumab

Trials testing the same drug.

NCT07003295 — Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease R · Phase 2 · recruiting
NCT07502872 — TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-g · Phase 2 · not yet recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07480850 — Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma · Phase 2 · active not recruiting
NCT07261163 — Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma · Phase 2 · not yet recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04983888 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 11 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04983888.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing